Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease

Pharmacotherapy

Volumn 38, Issue 3, 2018, Pages 309-318

  Anderegg, Maxwell D ^a   Gums, Tyler H ^b   Uribe, Liz ^a   MacLaughlin, Eric J ^c   Hoehns, James ^a,d   Bazaldua, Oralia V ^e   Ives, Timothy J ^f   Hahn, David L ^g   Coffey, Christopher S ^a   Carter, Barry L ^a,h  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Northeast Iowa Medical Education Foundation   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNC Hamner Institute for Drug Safety Sciences   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

chronic kidney disease; diabetes; hypertension; team based care

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLUSTER ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PATIENT CARE; PHARMACIST; POST HOC ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; COOPERATION; INTERDISCIPLINARY COMMUNICATION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHARMACY (SHOP); PHYSICIAN;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CLUSTER ANALYSIS; COOPERATIVE BEHAVIOR; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PHARMACISTS; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 85042382778     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.2083     Document Type: Article

References (45)

1. High Blood Pressure Fact Sheet: Centers for Disease Control and Prevention; [cited July 14, 2016]. Available from http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_bloodpressure.htm. Accessed December 20, 2017
2. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999–2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999–2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Available from http://wonder.cdc.gov/ucd-icd10.html. Accessed December 20, 2017.
3. Vinik A, Flemmer M. Diabetes and macrovascular disease. J Diabetes Complications 2002;16(3):235–45.
4. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):90–6.
5. Daly C. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007;22(Suppl 9):ix19–25.
6. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6):659–63.
7. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993;11(3):319–25.
8. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;5(Suppl):I80–93.
9. National Center for Health Statistics. Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville, MD; 2016.
10. Suh DC, Kim CM, Choi IS, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988–2004. J Hypertens 2009;27(9):1908–16.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703–13.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317(7160):713–20.
13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253–9.
14. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008;52(5):818–27.
15. Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999–2004. Am J Nephrol 2009;30(1):44–54.
16. Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008;121(4):332–40.
17. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 2014;47(1):86–99.
18. Carter BL, Ardery G, Dawson JD, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med 2009;169(21):1996–2002.
19. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3(2):e000718.
20. Bove AA, Santamore WP, Homko C, et al. Reducing cardiovascular disease risk in medically underserved urban and rural communities. Am Heart J 2011;161(2):351–9.
21. Von Muenster SJ, Carter BL, Weber CA, et al. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci 2008;30(1):128–35.
22. Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2011;34(1):20–6.
23. Edelman D, Fredrickson SK, Melnyk SD, et al. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Ann Intern Med 2010;152(11):689–96.
24. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118(3):276–84.
25. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm 2006;63(21):2116–22.
26. McLean DL, McAlister FA, Johnson JA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med 2008;168(21):2355–61.
27. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes 2015;8(3):235–43.
28. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee On Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560–72.
29. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545–59.
30. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507–20.
31. Carter BL, Clarke W, Ardery G, et al. A cluster-randomized effectiveness trial of a physician-pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes 2010;3(4):418–23.
32. Billups SJ, Okano G, Malone D, et al. Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. Am J Health Syst Pharm 2000;57(1):29–39.
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461–70.
34. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23(10):433–41.
35. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45(1):142–61.
36. Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich) 2008;10(4):260–71.
37. Gums TH, Uribe L, Vander Weg MW, James P, Coffey C, Carter BL. Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens 2015;9(7):569–78.
38. Anderegg MD, Gums TH, Uribe L, Coffey CS, James PA, Carter BL. Physician-pharmacist collaborative management: narrowing the socioeconomic blood pressure gap. Hypertension 2016;68(5):1314–20.
39. Smith SM, Carris NW, Dietrich E, et al. Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. J Am Soc Hypertens 2016;10(4):307–17.
40. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA 2016;315(24):2673–82.
41. Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017. https://doi.org/10.1016/j.jacc.2017.11.006. Available from https://www.sciencedirect.com/science/article/pii/S0735109717415191?via%3Dihub. Accessed February 11, 2018.
42. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005;28(4):771–6.
43. Carter BL. Primary care physician-pharmacist collaborative care model: strategies for implementation. Pharmacotherapy 2016;36(4):363–73.
44. Isetts BJ, Buffington DE, Carter BL, Smith M, Polgreen LA, James PA. Evaluation of pharmacists' work in a physician-pharmacist collaborative model for the management of hypertension. Pharmacotherapy 2016;36(4):374–84.
45. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol 2006;22(10):855–60.